Sociedad Americana de Hirudoterapia

The regulation of p42/p44 mitogen-activated protein kinases in the injured rat carotid artery

Research article published in Journal of surgical research (1997)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Preclinical (animal)Desarrollo de fármacosLille ST et al. · Journal of surgical research, 1997

Abstract

UNLABELLED: Arterial smooth muscle cell (SMC) proliferation is an important factor in the development of atherosclerotic plaques and restenotic lesions following arterial reconstruction. Basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), and thrombin are known to induce SMC proliferation and migration in vitro and in vivo. In cultured cells the proliferative responses to these mitogens depend on the activation of the p42/p44 mitogen-activated protein kinases (MAPKs), whereas the role of these kinases in vivo has yet to be established. We tested whether MAPK activity is induced following vessel injury and whether activity is dependent on the release of bFGF, PDGF, and thrombin. Following balloon injury of the left carotid of male Sprague-Dawley rats, arteries were removed and analyzed with respect to MAPK activity, BrdU-labeled nuclei, and/or luminal, medial, and intimal areas. MAPK activity is induced in the rat carotid artery following balloon-catheter injury with a maximum activation at 30 min with a return to just above baseline at 11 hr after injury. Intravenous administration of heparin or neutralizing antibodies to bFGF or PDGF prior to injury reduced SMC proliferation and neointimal lesional formation but did not affect the early induction of MAPK activity. Administration of a tissue factor inhibitor or thrombin inhibitor also did not affect MAPK activity, although it impaired the initiation of the coagulation cascade. IN CONCLUSION: (1) MAPK is activated in a time-dependent manner in response to injury; (2) the antiproliferative effect of heparin in vivo is not mediated through the inhibition of MAPK activity induced 30 min after injury; (3) the activation of MAPK after 30 min is not dependent on PDGF, bFGF, or thrombin following vessel injury in the rat.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, U.S. Gov't, P.H.S.
Indexed MeSH termsAnimalsBlood CoagulationCalcium-Calmodulin-Dependent Protein KinasesCarotid ArteriesCarotid Artery InjuriesCatheterizationEnzyme ActivationFibroblast Growth FactorsHeparinHirudinsMaleMitogen-Activated Protein Kinase 1

Resumen

The regulation of p42/p44 mitogen-activated protein kinases in the injured rat carotid artery.

Por qué esto importa para la hirudoterapia

Este estudio investigó la activación de las proteínas quinasas activadas por mitógenos (MAPKs) p42/p44 en arterias carótidas de rata tras una lesión con catéter-balón, evaluando si dicha activación depende de la trombina, del factor de crecimiento fibroblástico básico o del factor de crecimiento derivado de plaquetas. Los investigadores hallaron que, si bien la heparina y los anticuerpos neutralizantes redujeron la proliferación de células musculares lisas, la activación temprana de MAPK no dependió de la trombina ni de los demás factores analizados. Si bien el estudio aborda vías hemostáticas vasculares que se enmarcan en el dominio más amplio ASH, el resumen proporcionado no contiene absolutamente ninguna mención a sanguijuelas, hirudina ni hirudoterapia. Por lo tanto, basándose estrictamente en el texto proporcionado, la relevancia respecto a la terapia con sanguijuelas o al secretoma de la sanguijuela es totalmente inexistente.

Citación

The regulation of p42/p44 mitogen-activated protein kinases in the injured rat carotid artery

Lille ST et al. · Journal of surgical research, 1997

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.